News
Fertility drug improves live birth rates in women undergoing IVF

New research has demonstrated the effectiveness of a non-hormonal drug in increasing embryo implantation, pregnancy and live birth rates among women undergoing IVF and ICSI.
The findings, presented at the ESHRE 40th annual meeting in Amsterdam, represent a significant step toward the first therapeutic tool to increase embryo implantation and live birth rate success.
Worldwide, one in six people of reproductive age experience infertility in their lifetime. Over three million IVF cycles are performed annually and yet, despite advancing IVF technologies, embryo implantation failure remains a significant challenge.
In response to this unmet need, researchers have unveiled the promising findings of their Phase 2 clinical trial, OXOART2. The trial, conducted across 28 centres in Europe, evaluated OXO-001, a drug that acts directly on the endometrium to improve embryo implantation and pregnancy rates.
The study analysed 96 women aged up to 40 years old who underwent a single embryo transfer, 42 receiving placebo and 54 receiving a daily dose of OXO-001. Treatment began one menstrual cycle before the embryo transfer cycle and continued until five weeks after the transfer.
Statistically significant improvements were observed in biochemical pregnancy rates – an early detection of pregnancy – with rates of 75.9 per cent in the OXO-001 group compared to 52.4 per cent in the placebo group.
Clinically relevant improvements were also seen in clinical pregnancy rates and in ongoing pregnancy rates, being a +14.3 absolute increase (50.0 per cent for OXO-001 vs. 35.7 per cent for placebo) and a +10.6 absolute increase (46.3 per cent for OXO-001 vs 35.7 per cent for placebo) respectively.
Most importantly, there was an absolute increase of +6.9 in live birth rates (42.6 per cent for OXO-001 vs. 35.7 per cent for placebo).
Dr Agnès Arbat, OXOLIFE’s CEO and CMO, said: “From scientific societies, key opinion leaders, clinicians and patients, we know that an absolute increase of more than five percentage points in ongoing pregnancy is considered clinically meaningful.
“We observed an increase higher than +9, giving renewed hope to patients and the scientific community. We look forward to advancing this promising treatment through the next phases of clinical development.”
The occurrence of side effects was similar in both groups. The most common side effects were headaches, nausea, vomiting, gastrointestinal issues and dizziness, most of which were mild to moderate.
In the six-month follow-up, the babies indicated good development with no differences with placebo, the research showed and overall, OXO-001 was well tolerated.
Dr Ignasi Canals, CSO of OXOLIFE said: “We are thrilled with the results of this trial, which highlight OXO-001’s potential to become the first therapeutic treatment to increase embryo implantation success, with a non-hormonal drug using a new mechanism of action, acting directly on the endometrium.”
Professor Dr Karen Sermon, chair of ESHRE, added: “Despite continuous developments in ovarian stimulation, embryo manipulation and culture, improving live birth rates in medically assisted reproduction has been incremental at best.
“A jump of nearly seven per cent is very good news for our patients, and hopefully this can be confirmed in larger patient groups.”
To receive the Femtech World newsletter, sign up here.
Events4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Entrepreneur4 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion4 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up
Fertility2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health6 days agoLifting weights shows mental health and cognitive benefits in older women, study finds















